C2 Human
Human Plasma.
Complement C2, C3/C5 convertase, C2.
Sterile Filtered solution.
Greater than 95.0% as determined by SDS-PAGE.
Description
Human Complement C2 produced in Human plasma having a molecular mass of 93 kDa.
Product Specs
C2, the proteolytic subunit of both the C3 and C5 convertases, plays a crucial role in the complement system's activation pathways. Upon pathway initiation, enzyme complexes form on target surfaces. C1s and MASP, components of these complexes, activate both C4 and C2. They cleave a specific peptide bond in C4, leading to the deposition of C4b on the surface. Additionally, they cleave C2 into two fragments.
Human Complement C2, derived from human plasma, has a molecular weight of 93 kDa.
This product is provided as a sterile filtered solution.
This product is formulated in a buffer containing 25mM sodium phosphate and 100mM NaCl, at a pH of 6.0.
For optimal stability, store Human C2 at 4°C. If using the entire vial, it can be stored at 4°C for 2-4 weeks. For long-term storage, freeze the product below -20°C. It is recommended to add a carrier protein (0.1% HSA or BSA) for long-term storage to enhance stability. Avoid repeated freeze-thaw cycles to preserve product integrity.
The purity of this product is greater than 95.0% as assessed by SDS-PAGE analysis.
Each plasma donor undergoes rigorous testing to ensure the absence of antibodies against HIV-1, HIV-2, HCV, and HBsAg. Only plasma that tests negative for these viruses is used for production.
Complement C2, C3/C5 convertase, C2.
Human Plasma.
Product Science Overview
Complement C2 is essential for the activation of the classical and lectin pathways of the complement system. When the body detects a foreign invader, the complement system is activated. Complement C2 binds to an activated surface-bound C4b in the presence of magnesium ions (Mg²⁺), forming the C4bC2 complex. This complex is then cleaved by C1s or MASP2 into C2a and C2b . The C2a fragment remains bound to C4b, forming the C3-convertase (C4b2a), which is crucial for the subsequent steps in the complement activation cascade .
Deficiency in Complement C2 is the most common genetically determined complete complement deficiency. It is associated with a number of diseases, most notably recurrent serious infections in young children and the development of systemic lupus erythematosus (SLE) in adults . The deficiency of C2 can lead to increased susceptibility to bacterial infections and a higher risk of developing autoimmune diseases .
Research has shown that recombinant human complement component C2 can restore classical complement pathway activity in vitro. This has potential therapeutic implications for treating C2 deficiency diseases . For instance, infusions with normal fresh frozen plasma have demonstrated therapeutic effects, but protein replacement therapy has not yet been fully evaluated .
